Immunotherapy for lung cancer — who actually benefits, and how much

No. Most people diagnosed with lung cancer in India are not offered immunotherapy as their first treatment. Early-stage disease is treated with surgery or radiation. A large share of Indian lung adenocarcinomas carry an EGFR mutation or an ALK rearrangement, where a targeted tablet works better. Immunotherapy applies to a defined subgroup.

Lung cancer is still the single largest immunotherapy audience in India, because it is one of the most commonly diagnosed cancers here and because checkpoint inhibitors were approved for it earliest. That is exactly why this page starts with who it is not for. The most common way a family arrives at CION disappointed is having read about immunotherapy for lung cancer, arranged the money, and then learned at the consultation that their own report pointed somewhere else entirely.

There are four common reasons it is not the first step. The cancer is stage I or II and can be removed with surgery. The biopsy shows a sensitising EGFR mutation, an ALK rearrangement or another targetable alteration, and an oral targeted drug is the better opening move. The patient is too unwell for systemic therapy of any kind to be safe. Or an existing autoimmune condition, an organ transplant, or an ongoing need for high-dose steroids makes checkpoint blockade unsafe without specialist assessment.

None of this is a reason to stop asking. It is a reason to get the tests done in the right order before committing money to a treatment your report may not support. CION coordinates driver-mutation and PD-L1 testing through accredited partner pathology laboratories, and every result is reviewed by a tumour board rather than by one doctor alone.

Groups are simplified for patient education and follow NCCN, ESMO and ASCO guidance, indicative as of August 2026. The percentages shown are objective response rates — measurable tumour shrinkage in published registration-trial populations. They are not survival figures and they do not predict any individual outcome. Only your treating oncologist, reading your actual reports, can say which row applies to you.

1. 1

   Confirm the exact type of lung cancer

   A biopsy or cell block establishes whether this is non-small cell lung cancer (adenocarcinoma, squamous or other) or small cell lung cancer. The whole pathway forks here, and immunotherapy is used differently on each side.

2. 2

   Test for driver mutations first

   EGFR, ALK, ROS1 and other targetable alterations are looked for before anything else. A positive result usually means an oral targeted drug is the better first treatment, and it changes whether immunotherapy is appropriate at all.

3. 3

   Score PD-L1

   PD-L1 immunohistochemistry gives a tumour proportion score, or TPS. In non-small cell lung cancer, a TPS of 50% or above is generally treated as high and 1–49% as low positive. This influences whether a checkpoint inhibitor is used alone or with chemotherapy.

4. 4

   Assess whether you can tolerate it

   Lung function, existing autoimmune disease, transplant history, current steroid dose, kidney and liver function and your performance status are all reviewed. Checkpoint blockade is not a gentle treatment simply because it is not chemotherapy.

5. 5

   Tumour board decides — including the option of not treating

   Medical, surgical and radiation oncologists review your case together. The recommendation may be immunotherapy, chemotherapy, targeted therapy, radiation, supportive care, or a combination. Choosing not to give immunotherapy is a legitimate outcome and is explained to you plainly.

6. 6

   Cost and scheme cover discussed before the first cycle

   Immunotherapy is a running cost across many cycles, not a one-time bill. Cover under Aarogyasri, Ayushman Bharat, CGHS, ECHS or private insurance differs by scheme and indication, and any estimate you are given is indicative, as of August 2026.

In selected advanced non-small cell lung cancer trial populations, checkpoint inhibitors produced measurable tumour shrinkage in roughly 40–45% of patients with a high PD-L1 score, and roughly 45–50% when combined with chemotherapy. Those are group figures from published registration trials referenced in NCCN and ESMO guidance, indicative as of August 2026 — not predictions for one person.

Three things get confused when people search for a success rate. Objective response rate is the share of patients whose tumours measurably shrank on a scan. Disease control rate adds those whose disease simply stayed stable. Neither is a survival figure. This page deliberately does not attach survival numbers to a treatment choice, because such figures come from selected trial populations and mislead badly when applied to one individual sitting in a consulting room.

Response also behaves differently here than with chemotherapy. Some tumours shrink slowly over months. Some scans show apparent enlargement early, as immune cells flood into the tumour, before shrinkage follows — which is why one scan is rarely acted on alone. And in a proportion of patients the tumour does not respond at all, which is usually clear early enough to change the plan. Response-assessment imaging, including PET-CT, is coordinated at partner imaging centres and reviewed with your oncologist.

If anyone quotes you a percentage that supposedly applies to you before your biomarker reports are back, that number is not coming from your case. Ask which population it came from, and when.

• Given as day care — Infusions are administered as day care at CION centres. You are monitored during and after the infusion and go home the same day.
• A cycle rhythm, not a single dose — Depending on the regimen, infusions run every two, three or six weeks, and continue while the treatment is working and tolerated.
• Bloods before every cycle — Thyroid, liver, kidney function and blood counts are checked before each infusion, because immune side effects often show in bloodwork before symptoms.
• Side effects that behave differently — Immune-related effects can appear in the gut, lungs, skin, thyroid, liver or heart, sometimes weeks after a dose and occasionally after treatment ends.
• Anything new is reported, not waited out — Loose motions, breathlessness, chest pain, a new rash or unusual tiredness should reach your team the same day — call 1800 202 8726 if you cannot reach your treating doctor.
• Cost planned across cycles, not per bill — Scheme eligibility under Aarogyasri, Ayushman Bharat, CGHS, ECHS or private insurance is checked before you start. Any estimate given is indicative, as of August 2026.

Consultations at CION run 45 minutes, and the option of not starting immunotherapy is discussed as seriously as starting it. Decisions for healing, not billing.

• PD-L1 Testing in Lung Cancer: What Your Score Means — the test that decides whether a checkpoint inhibitor is used alone or alongside chemotherapy.
• Immunotherapy Alone or With Chemotherapy for Lung Cancer? — how that fork is argued in a tumour board, and what tips it either way.
• EGFR and ALK Mutations: Why Immunotherapy May Not Be for You — read this first if your report already names a driver mutation.
• Immunotherapy at CION Cancer Clinics — how the whole pathway runs, from biomarker testing to infusion day care and follow-up.

This page is general patient education about immunotherapy in lung cancer and does not interpret any individual report or recommend a specific medicine. Biomarker testing and response-assessment imaging are coordinated at accredited partner laboratories and imaging centres. Guideline positions and cost figures are indicative, as of August 2026, and change over time. Bring your reports to a consultation for an assessment of your own situation.

Lung cancer families walk this road with us every week

The hardest part is rarely the infusion. It is the waiting, the reports, and not knowing which questions to ask. Our team takes 45 minutes to answer them properly.